Public Company News

Baozun Announces Second Quarter 2024 Unaudited Financial Results

SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- Baozun Inc. (Nasdaq: BZUN and HKEX: 9991) ("Baozun", the "Company" or the "Group"), a leading brand e-commerce solution provider and digital commerce enabler inChina, today announced its unaudited financial results for the second quarter endedJune 30, 2024....

2024-08-28 18:35 5127

Mega Matrix Announces FlexTV's Surge to Top 4 on the App Store Entertainment Chart (Free Apps, Saudi Arabia) as of August 27, 2024

PALO ALTO, Calif., Aug. 28, 2024 /PRNewswire/ -- Mega Matrix Corp. ("MPU" or the "Company") (NYSE American: MPU), today announced that FlexTV, its short drama streaming platform, has ranked No.4 in the App Store Entertainment Chart (Free Apps,Saudi Arabia) as of August 27, 2024. 

2024-08-28 18:30 2525

Infosys Joins Stanford HAI Affiliate Program to Accelerate Enterprise AI Research Initiatives

Leveraging Infosys Topaz, the initiative will focus on key areas to drive innovation and accelerate enterprise AI adoption BENGALURU, India, Aug. 28, 2024 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services ...

2024-08-28 18:28 2659

Tigermed Reports 2024 Interim Results

HANGZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its int...

2024-08-28 18:26 4747

Record High Interim Dividend Declared as Net Profit Soars----CNOOC Limited Announced Its 2024 Interim Results

HONG KONG, Aug. 28, 2024 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announced today its 2024 interim results. * Making solid progress in reserves and production growth, net production increases by 9.3% year-on-year ("YoY") ...

2024-08-28 18:17 3579

Fosun Pharma Announces 2024 Interim Results

Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its o...

2024-08-28 18:10 5879

Quhuo Reports Unaudited Financial Results for the First Half of 2024

BEIJING, Aug. 28, 2024 /PRNewswire/ -- Quhuo Limited (NASDAQ: QH) ("Quhuo," the "Company," "we" or "our"), a leading gig economy platform focusing on local life services inChina, today reported its unaudited financial results for the six months endedJune 30, 2024. Financial and Operational Highl...

2024-08-28 18:00 3017

Quhuo Announces Unaudited Financial Results for the First Half of 2024: Precise Strategy Spurs Strong Growth in Mobility Service and Homestay

* Revenues from mobility service solutions were RMB100.5 million (US$13.8 million), representing an increase of 71.7% year-over-year. * Quhuo International shipped 815 vehicles under its vehicle export solutions. * The Company has expanded services to 132 cities nationwide, representing a 21....

2024-08-28 18:00 3300

Harbour BioMed Announces 2024 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology an...

2024-08-28 17:44 3337

Kerry Logistics Network Posts 126% Growth in Profit Attributable to the Shareholders, Outperforms the Market in terms of Growth in Core Net Profit

HONG KONG, Aug. 28, 2024 /PRNewswire/ -- Kerry Logistics Network Limited ('Kerry Logistics Network' or together with its subsidiaries, the 'Group' or 'KLN Group'; Stock Code 0636.HK) today announced the Group's interim results for the six months ended30 June 2024. Group's Financial Highlights ...

2024-08-28 17:43 3447

Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization

* "Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" * "While maintaining the current process for emergency use authorization for mild-to-moderate COVID-19 patients, Hyundai Bioscience will expedite Phase 3 clinical tr...

2024-08-28 17:29 2992

DPC Dash Ltd Announces 2024 Interim Financial Results

Revenues increased to RMB2.04 billion, representing 48.3% year-over-year growth Adjusted net profit reached RMB50.9 million, from an adjusted net loss of RMB17.4 million in the same period of 2023 Store-level operating profit grew by 59.0%; Adjusted group EBITDA increased by 83.7% Added 146 net...

2024-08-28 17:20 6301

Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical

SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiary, Achieva Medical Limited ("Achieva Medical"), entered ...

2024-08-28 16:40 3943

Haitian Mexico Open Day: A New Chapter of Regional Strategy

GUADALAJARA, Mexico, Aug. 27, 2024 /PRNewswire/ -- In mid-August, Haitian Mexico held a grand Open Day inGuadalajara, Mexico. This event not only allowed local customers to learn about Haitian International's latest technological innovations but also served as a comprehensive display of the compa...

2024-08-28 15:47 2562

"Bleach: Brave Souls" 95 Million Downloads Celebration Campaign Begins Alongside the Thousand-Year Blood War Zenith Summons: Preeminence

TOKYO, Aug. 28, 2024 /PRNewswire/ -- KLab Inc., a leader in online mobile games, announced that its hit 3D action game Bleach: Brave Souls has reached a total of 95 million downloads* worldwide. See theoriginal press release (https://www.klab.com/en/press/

2024-08-28 15:40 2695

Hyundai Motor Unveils New 'Hyundai Way' Strategy and Outlines Mid- to Long-Term Goals at 2024 CEO Investor Day

* Hyundai Motor details a flexible response approach to market conditions and focus on electrification through its 'Hyundai Way' strategy …    Targeting 5.55 million annual global sales by 2030, up 30% from 2023 …    Aiming to sell 2 million EVs per year globally by 2030 …    Plan to introduce...

2024-08-28 14:52 3631

Tested and Proven: Sungrow's AFCI 3.0 Ensures Safety in Large-Scale C&I Power Plants

HO CHI MINH CITY, Vietnam, Aug. 28, 2024 /PRNewswire/ -- The DC arcing remains a significant concern in the PV industry, often being the primary catalyst for fires. As solar installations increase in scale and longevity, the risks tied to DC arcing have risen, necessitating advances in detection ...

2024-08-28 14:37 3349

Coway Gets Closer to Its Environmental Goals through ESG Initiatives

- The company has aimed for a 100% reduction in greenhouse gas emissions by 2050 through 'carbon neutrality.' SEOUL, South Korea, Aug. 28, 2024 /PRNewswire/ -- Back in 2006, Coway, true to its name as the "Best Life Solution Company," pledged to follow an ESG framework that would minimize the en...

2024-08-28 13:00 3668

Air Products and Tatung Forever Energy Sign Power Purchase Agreement for Solar Electricity in Taiwan

TAIPEI, Aug. 28, 2024 /PRNewswire/ -- Air Products (NYSE: APD), a world-leading industrial gases company,today announced Air Products San Fu Co. Ltd. has signed a 10-year Power Purchase Agreement (PPA) for solar electricity with Tatung Forever Energy, a subsidiary of Tatung Company, one ofTaiwan'...

2024-08-28 11:00 5299

Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist

SEOUL, South Korea, Aug. 27, 2024 /PRNewswire/ -- Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has cleared the IND application of Phase 1 Multiple Ascending Dose (MAD) study for ID110521156, an oral...

2024-08-28 10:43 2661